Nearing All-Time Highs
Traders Cafe with Zak Mir: Bulletin Board Heroes, Friday 13th January 2023 via Vox Markets
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Dax, Dow, Bitcoin, Argo,
RNS Hotlist with Zak Mir: PANR, OKYO, PHE, OBE, BEN, HARL, TOM, IES, NTOG, PRD, MOS & CRTM
Recent bear target Pantheon Resources (PANR), the AIM-quoted oil company, provided an operational update on the Alkaid #2 well.
OKYO Pharma LTD (AIM:OKYO) Interim Results for the Six Months Ending 30 September 2022
OKYO Pharma Limited (LSE: OKYO, NASDAQ: OKYO),— an ophthalmology-focused bio-pharmaceutical company developing OK-101 to treat Dry Eye Disease (DED) to address the significant unmet need in this multi-billion-dollar market, today
Traders Cafe with Zak Mir: Bulletin Board Heroes, Thursday 22nd December 2022 via Vox Markets
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Dax, Dow, Bitcoin, Bushveld,
RNS Hotlist with Zak Mir: OKYO, BEN, WSBN, I3E, IOG, SEE, GROC, ATM, AAA, TERN & HARL via Vox Markets
OKYO Pharma (OKYO), an ophthalmology-focused bio-pharmaceutical company, announced that it has received clearance of its Investigational New Drug (IND) application from the FDA to initiate a Phase 2, first-in-human, clinical
OKYO Pharma Limited (AIM:OKYO) U.S. FDA Clearance of IND Application for OK-101
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease
RNS Hotlist with Zak Mir: ORR, GCAT, ZPHR, POLB, COPL, HUI, OKYO, PRE, COOK, BLOE & THR via Vox Markets
We perhaps found out today why shares of Oriole Resources (ORR) have been such a firm market of late. The AIM-quoted gold exploration company reported that its partner IAMGOLD Corporation
OKYO Pharma Limited (AIM:OKYO) OKYO to Participate at Biotech Showcase
London and New York, NY., 21 December, 2022 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to
RNS Hotlist with Zak Mir: LIFS, UOG, TXP, OKYO, SED, CTL, BRES, EDL, AFN, VAL, HE1, NCYT, SCIR, ECHO & VNET via Vox Markets
LifeSafe (LIFS), a fire safety technology business, provides a trading update for the eleven month period ended 30 November 2022. The company reported that sales growth through the Group’s consumer
OKYO Pharma LTD (AIM:OKYO) publicly files a registration statement with the SEC
LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease